Fc epsilon RI alpha / IgE Fc Produktliste
Species
- Human（1）
| Cat. No. | Product Name | Size&Price | Add to Cart |
|---|---|---|---|
Human Fc epsilon RI alpha / IgE Fc Inhibitor Screening Kit (TR-FRET) | $770.00 100tests |   |
You Have Viewed 1-1 Of 1 Results
Asset Licensing Opportunity
Resources
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Prostate cancer vaccine (Advaxis) | ADXS-PSA; ADXS-31142 | Phase 2 Clinical | Advaxis Inc | Neoplasms; Prostatic Neoplasms | Details |
| TP-122A | TP-122A | Phase 2 Clinical | Vector B2B, Technophage SA | Pneumonia, Ventilator-Associated | Details |
| GEA-408 | GEA-408 | Phase 2 Clinical | GenEros Biopharma Hangzhou Ltd | Prostatic Neoplasms | Details |
| P-PSMA-101 | P-PSMA-101 | Phase 1 Clinical | Poseida Therapeutics Inc | Genital Neoplasms, Male; Salivary Gland Neoplasms; Neoplasms; Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Acinar Cell; Urogenital Neoplasms; Prostatic Diseases | Details |
| Prostate cancer subunit vaccine (Progenics) | Phase 1 Clinical | Progenics Pharmaceuticals Inc | Prostatic Neoplasms | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Afala | Approved | Materia Medica Holding Research And Production Company | Russian Federation | Prostatic Neoplasms; Prostatitis | Materia Medica Holding Research And Production Company | 2014-01-01 | Prostatic Neoplasms; Prostatitis | Details |
Customer Reviews